Drug Trial Radar · NCT05598268
A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Oct 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
74
Planned (sponsor's estimate)
Start
Mar 1, 2022
Primary completion
Jun 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- ImmVira Pharma Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label study conducted in 3 phases: Dose escalation stage: The stage contain 4 cohorts, each cohort divided into 2 groups (group A, single dose and Group B, multiple dose).Dose escalation will use a 3+3 design to evaluate escalating doses of T3011.Cohorts of three subjects will be enrolled at each T3011 dose level with expansion to six subjects, if necessary, to assess toxicity. Total enrollment will depend on the toxicities observed, with approximately 4-24 evaluable subjects enrolled in dose escalation stage. Dose extension stage: The SMC will evaluate the available safety and preliminary efficacy data and initiate dose-expansion studies for the appropriate indications Phase IIa: To explore the safety of intravenous administration and expand the study in other indications. the stage will be carried out gradually based on the data obtained from the phase I study.
Conditions
- Advanced Solid Tumor
- Lung Cancer
- Liver Cancer
- Lymphoma
- Mesothelioma of Pleura
Interventions
T3011Biological
T3011 will be administered through IV drip
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of escalating doses of IV T3011 in Patients with advanced malignant tumorsTime frame: Up to 2 years from first dose of T3011
- Assess DLTs and identify the RP2D of single agent IV T3011Time frame: Up to 2 years from first dose of T3011
- Assess safety and tolerability of T3011 intravenous administration at MTD or RP2D doses through dose extension studyTime frame: Up to 2 years from first dose of T3011
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital
Beijing, China · Recruiting
Shanghai Chest Hosptial
Shanghai, China · Recruiting
The First Affiliated Hospital of Bengbu Medicial College
Bengbu, Anhui, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guanzhou, Guangdong, China · Recruiting
the First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Recruiting
Henan Cancer Hosptial
Zhengzhou, Henan, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.